ABSTRACT In dispersed acini from.guinea pig pancreas, proglumide (DL-4-benzamido-N, N-dipropylglutaramic acid) and benzotript (N-p-chlorobenzoyl-L-tryptophan) caused a rightward shift in the dose-response curve for cholecystokinin-stimulated amylase secretion but did not alter the maximal increase in amylase secretion caused by cholecystoldnin.. At relatively low, concentrations, proglumide did not alter the stimulation ofenzyme secretion caused by secretagogues whose effects are mediated by adenosine 3'5'-monophosphate (e.g., vasoactive intestinal peptide or secretin) and did not alter the stimulation of enzyme secretion caused by secretagogues that have a mode of action similar to that of cholecystokinin but act through different receptors (e.g., bombesin, physalaemin, eledoisin, and ionophore A23187). There was a close correlation between the ability of proglumide or benzotript to inhibit binding of '25I-labeled cholecystokinin to its receptors on pancreatic acini and the abilities ofthese compounds to inhibit the action of cholecystokinin on enzyme secretion and on calcium outflux. These results indicate that proglumide and benzotript are members ofa different class ofcholecystokinin receptor antagonists.
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Proglumide ( Fig. 1 ) is a derivative of glutaramic acid that has been used for approximately 10 years in Europe and Japan to treat patients with peptic ulcers. (1, 2) . The claimed effectiveness of proglumide has been attributed to its ability to reduce secretion ofgastric acid (1, 2); however, the mechanism ofaction ofproglumide has not been established. Some studies have con- cluded that proglumide inhibits only gastrin-stimulated acid secretion and does not have anticholinergic or antihistamine activity (2) (3) (4) (5) , whereas other studies report that proglumide can inhibit the stimulation of acid secretion caused by gastrin, histamine, carbamoylcholine, and insulin (3, (6) (7) (8) . Proglumide has been reported to inhibit gastrin-stimulated acid secretion competitively (3) as well as noncompetitively (5, 9) and to inhibit binding of radiolabeled gastrin to a heterogeneous mixture of gastric mucosal cellst as well as to a crude preparation ofgastric mucosal membranes (10) . Proglumide has also been reported to alter the action ofcaerulein on gallbladder muscle and gastric pyloric muscle, gastric acid secretion, and pancreatic fluid secretion (11) .
Because gastrin, cholecystokinin (CCK), and caerulein have a common COOH-terminal pentapeptide amide (12) and exert their effects on a particular target tissue by interacting with the same class of receptors (13) (14) (15) , and because proglumide has been reported to inhibit the actions ofboth gastrin and caerulein (3, 5, 11), we considered the possibility that proglumide is a specific antagonist of the interaction of CCK and structurally related peptides with their cell surface receptors. To examine this possibility we tested the abilities of proglumide and benzotript ( Fig. 1) , a derivative of tryptophan that has actions similar to those of proglumide (2) , to alter the actions of CCK as well as other secretagogues on dispersed acini from guinea pig pancreas. In addition, we compared the actions of proglumide and benzotript to those of Bt2cGMP, a compound that we (13, 16) and others (15) (16) (17) (18) (19) lution was equilibrated with 100% 02 and all incubations were performed with 100% 02 as the gas phase. Methods. Dispersed acini from guinea pig pancreas were prepared by using the published procedure (20) with three minor modifications: (i) The digestion solution contained collagenase at a concentration of 0.12 mg/ml. (ii) After digestion solution had been injected into the pancreas, the tissue was incubated with 5 ml of digestion solution for four sequential 10-min periods instead of one 15-min period followed by two 10-min periods. (iii) The tissue was washed with standard incubation solution only after the third. 10-min digestion period instead of after each digestion period.
Amylase release was measured by using the reported procedure (20, 21) . Acini from the pancreas of one animal were suspended in 150 ml of standard incubation solution and samples (1.0 ml) were incubated with the appropriate agents for 30 min at 37°C. Amylase activity was determined by the method of Ceska et al. (22, 23) , using the Phadebas reagent. Amylase release was calculated as the percentage of the amylase activity in the acini at the beginning of the incubation that was released into the extracellular medium during the incubation.
Outflux of 'Ca was determined by using the described procedure (24) . Acini from the pancreas of one animal were suspended in 10 ml of standard incubation solution and, after the acini were loaded with ',Ca, they were washed and incubated with the appropriate agents for 5 min at 37C. Outflux of 45Ca was calculated as the percentage of the 'Ca in the acini at the beginning of the 5-min incubation that was released into the extracellular-medium during the incubation.
Binding of "MI-labeled CCK ('25I-CCK) to pancreatic acini was determined as described (13) . '25I-CCK was prepared by using the published modifications (13) of the procedure of Bolton and Hunter (25) . The specific activities of the various preparations of 125I-CCK used in the present studies were 900-1300 Ci/mmol. Acini from the pancreas of one animal were suspended in 10 ml of standard incubation solution and incubated with the appropriate agents plus 50 pM 125I-CCK (approximately 70,000 cpm/ml of cell suspension) for 30 min at 37°C.
Nonsaturable binding of '25I-CCK was determined as the amount of radioactivity associated with the acini when the incubation contained 0.1 A1M CCK-8 and was always less than 20% of the total binding. In this paper all values for bound 125I-CCK represent saturable binding and were calculated as total binding minus nonsaturable binding.
RESULTS
In acini incubated with increasing concentrations of CCK-8, amylase secretion increased, became maximal with 0.3 nM CCK-8, and then decreased at peptide concentrations above 0.3 nM (Fig. 2) . Bt~cGMP (Fig. 2 Left) and proglumide (Fig. 2 Right) caused a rightward shift in the dose-response curve for CGK-8-stimulated amylase secretion, and the magnitude ofthe shift was proportional to the concentration of Bt2cGMP or proglumide. Results similar to those illustrated in Fig. 2 with Bt2cGMP or proglumide were also obtained with benzotript (not shown).
When acini were incubated with a fixed concentration of CCK-8, the pattern of action of Bt2cGMP or proglumide depended on the concentration of CCK-8 (Fig. 3) . With concentrations ofCCK-8 that were submaximal or maximal for causing amylase secretion, increasing concentrations of Bt2cGMP or proglumide produced a progressive decrease in amylase secretion, and each antagonist was more potent at the lower concentration of CCK-8 (Fig. 3) . amylase secretion to increase, become maximal, and, in the case of Bt2cGMP, then decrease (Fig. 3) . Table 1 illustrates that Bt2cGMP and proglumide inhibited the increase in enzyme secretion caused by secretagogues that interact with CCK receptors on pancreatic acini (i.e., CCK-8, caerulein, and gastrin) but did not alter basal enzyme secretion or the increase in enzyme secretion caused by -secretagogues that do not interact .with CCK receptors (i.e., physalaemin, eledoisin, bombesin, A23187, carbachol, VIP, secretin, or 8Br-cAMP).
Previously we have shown that there is a close correlation between the abilities of CCK and structurally related peptides to inhibit binding of 125I-CCK to pancreatic acini and their abilities to cause mobilization of cellular calcium and to stimulate enzyme secretion (13) . As illustrated in Fig. 4 32.3 ± 10 4.9 ± 0.3* 5.4 ± 0.9* Gastrin I-(=17) (1 ,uM) 35.0 ± 3.6 6.2 ± 3.6* 4.9 ± 0.6* Physalaemin (10 lase secretion caused by 1 nM CCK. In terms of the abilities of these compounds to antagonize these actions of CCK, the potency of proglumide was similar to that of benzotript (halfmaximal inhibition at approximately 500 ,uM; and benzotript were parallel to the curve for the inhibition caused by Bt2cGMP (Fig. 5) .
Because proglumide has been reported to have anticholinergic effects on gastric acid secretion (3), we examined the effect of proglumide on carbachol-stimulated amylase secretion in greater detail. Proglumide, when tested at a relatively high concentration (10 Fig. 6 ). Concentrations of proglumide of 3 mM or less did not alter the increase in amylase secretion caused by any concentration of carbachol tested (Fig. 6) . Benzotript (13, 16, 17) as well as other tissues (15, 19) .
The present findings indicate that proglumide, a derivative of glutaramic acid (Fig. 1) , and benzotript, a derivative of tryptophan (Fig. 1) (26, 27) . The present results illustrate that, like Bt2cGMP, proglumide and benzotript can reverse CCK-induced residual stimulation ofamylase secretion; therefore, proglumide and benzotript have the same spectrum of actions on CCK-induced changes in acinar cell function as do butyryl derivatives ofcyclic GMP (13, 16, 26, 27) . In terms oftheir chemical structures, however, proglumide and benzotript bear no obvious resemblance to butyryl cyclic GMP (Fig. 1) ; therefore, they appear to be members ofa different class ofCCK-receptor antagonists. Moreover, because proglumide and benzotript are relatively inexpensive and are active after oral administration to humans (1) and animals (4), these compounds may be useful in defining the role of CCK and related peptides in various physiological processes and may be oftherapeutic value in clinical conditions in which antagonizing the actions of CCK might be expected to produce beneficial effects.
